nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2013-2343nnp-257Research ArticleArticlesСтатьиThe efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's diseaseЭффективность агониста дофаминовых рецепторов ротиготина в лечении болезни ПаркинсонаNodelMarina RomanovnaNodelMarina Romanovnanodell_m@yahoo.comКафедра нервных болезней ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава РоссииРоссияDepartment of Nervous System Diseases, I.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaRussian Federation20130711201353NO3 (2013)6063Copyright © Nodel M.R., 20132013Nodel M.R.Nodel M.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/257

Rotigotine is a new, non-ergot dopamine receptor agonist (DRA) formulated as a transdermal drug delivery system. This article reviews the clinical efficacy and tolerability of Rotigotine transdermal patch in Parkinson's disease (PD) and discusses the results of clinical trials of Rotigotine in early- and late-stage PD. The Rotigotine transdermal patch is efficacious in the treatment of PD. Drug-related adverse events (AEs) include side effects typical for DRA, which are generally mild or moderate in intensity. The most common AEs are local reactions that are mild or moderate. Once-daily administration of the rotigotine transdermal patch is effective in the treatment of patients with early-stage PD as monotherapy and in combination with levodopa in late-stage PD and in inadequate morning motor control despite antiparkinsonian treatment.

Ротиготин – новый неэрготаминовый агонист дофаминовых рецепторов (АДР), выпускается в форме трансдермальной транспортной системы. Представлен обзор клинической эффективности и переносимости трансдермального пластыря ротиготина при болезни Паркинсона (БП). Обсуждаются результаты клинических исследований ротиготина при ранних и поздних стадиях БП. Связанные с препаратом нежелательные явления (НЯ) включают типичные для АДР побочные реакции, которые обычно имеют легкую или умеренную степень выраженности. Наиболее частое НЯ –местные реакции, в большинстве случаев легко или умеренно выраженные. Трансдермальный пластырь ротиготин, применяемый 1 раз в день, эффективен в виде монотерапии ранней стадии БП, а также в комбинации с леводопой при поздних стадиях болезни и неадекватном утреннем контроле двигательных проявлений, несмотря на антипаркинсоническое лечение.

болезнь Паркинсоналеводопаагонисты дофаминовых рецепторовротиготинтрансдермальный пластырьтерапиякомплаентностьфлюктуациидискинезииParkinson's diseaselevodopadopamine receptor agonistsrotigotinetransdermal patchtherapycompliancefluctuationsdyskinesisReferences<div><p>Артемьев ДВ, Голубев ВЛ, Яхно НН. Болезнь Паркинсона. В кн.: Болезни нервной системы. Под. ред. Яхно НН. Москва: Медицина; 2005; 2. С. 76–96. [Artem'ev DV, Golubev VL, Yakhno NN. Bolezn' Parkinsona. V kn.: Bolezni nervnoy sistemy. Pod. red. Yakhno NN. Moscow: Meditsina; 2005;2. Р. 76–96.]</p><p>Голубев ВЛ. Лечение болезни Паркинсона: решенные и нерешенные вопросы. В кн.: Избранные лекции по неврологии. Под ред. Голубева ВЛ. Mосква: Эйдос Медиа; 2006. С. 395–421. [Golubev VL. Lechenie bolezni Parkinsona: reshennye i nereshennye voprosy. V kn.: Izbrannye lektsii po nevrologii. Pod red. Golubeva VL. Moskva: Eydos Media; 2006. Р. 395–421.]</p><p>Нодель МР. Леводопа: поиски стандартов для «золотого стандарта». Неврологический журнал. 2010;(3):42–7. [Nodel' MR. Levodopa: poiski standartov dlya «zolotogo standarta». Nevrologicheskiy zhurnal. 2010;(3):42–7.]</p><p>Шток ВН, Федорова НВ. Болезнь Паркинсона. В кн.: Экстрапирамидные расстройства. Под ред. Штока ВН и соавт. Москва: MЕДпресс-информ; 2002. С. 94–122. [Shtok VN, Fedorova NV. Bolezn' Parkinsona. V kn.: Ekstrapiramidnye rasstroystva. Pod red. Shtoka VN i soavt. Moscow: MEDpress-inform; 2002. S. 94–122.]</p><p>Ahlskog J, Muenter M. Frequency of lеvodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58. DOI: 10.1002%2Fmds.1090.</p><p>Brotchie J, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson’s disease. J Neural Transm. 2005;112(3):359-91. DOI: 10.1007%2Fs00702-004-0251-7. Epub 2004 Dec 22.</p><p>Olanow CW. The scientific basis for the current treatment of Parkinson’s disease. Ann Rev Med. 2004;55:41–60. DOI: 10.1146%2Fannurev.med.55.091902.104422.</p><p>Stocchi F, Vacca L, Ruggieri S, Olanow SW. Intermittent vs continuous levodopa administration in patient with advanced Parkinson’s disease: a clinical and pharmacokinetic study. Arch. Neurol. 2005;62(6):905–10.</p><p>The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinsons disease: A randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931–8.</p><p>Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson’s disease. Expert Opin Pharmacother. 2009;10(4):677–91. DOI: 10.1517/14656560902746041.</p><p>Rose S, Scheller DKA, Bredenbach A et al. Plasma level of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behav Pharmacol. 2007;18(2):155–60. DOI: 10.1097%2FFBP.0b013e3280ebb400.</p><p>The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinsons disease. Arch Neurol. 2003;60(12):1721–8.</p><p>Watts RL, Jankovic J, Waters C et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinsons disease. Neurology. 2007;68(4):272–6. DOI: 10.1212%2F01.wnl.0000252355.79284. 22 Epub 2007 Jan 3.</p><p>Poewe WH, Rascol O, Giladi N et al. Long-term experience with rotigotine transdermal patch. Eur J Neurol. 2006;13(Suppl 2):322.</p><p>Metman VL, Gillespie M, Farmer C et al. Continuous transdermal dopaminrtgic stimulation in advanced Parkinson’s disease. Clin. Neuropharmacol. 2001;24(3):163–9.</p><p>Lewitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson’s disease treated with rotigotine transdermal system: PREFER study. Neurology. 2007;68(16):1262–7.</p><p>Poewe WH, Rascol O, Quinn N et al. On behalf of the SP515 Investigators. Efficaсy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomized controlled trial. Lancet Neurol. 2007;6(6):513–20.</p><p>Giladi N, Badenhorst F, Boroojerdi B. Effects of rotigotine transdermal patch on early morning and night time motor function in patients with Parkinson’s disease. Eur J Neurol. 2007;14(Suppl 1):67.</p><p>Lewitt PA, Boroojerdi B, Macmahon D et al. Overnight switch from oral dopaminergic agonists to transdermal ritigitine patch in subjects with Parkinson’s disease. Clin Neuropharmacol. 2007;30(5):256–65.</p><p>Perez-Lloret S, Reya MV, Rattia PL, Rascol O. Rotigotine transdermal patch for thetreatment of Parkinson’s Disease. Fundam Clin Pharmacol. 2013;27(1):81–95. DOI: 10.1111/j.1472-8206.2012.01028.x. Epub 2012 Feb 9.</p><p>Giladi N, Boroojerdi B, Korczyn AD et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22(16):2398–404. DOI: 10.1002%2Fmds.21741. 22. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. Mov Disord. 2003;18(6):668–72. DOI: 10.1002%2Fmds.10429.</p><p>Giladi N, Badenhorst F, Boroojerdi B. Patients preference for rotigotine transdermal patch for treatment of Parkinson’s disease. Results of a single-arm, prospective, multinational trial. Eur J Neurol. 2007;14(Suppl 1):67.</p></div><br /><div><p>Артемьев ДВ, Голубев ВЛ, Яхно НН. Болезнь Паркинсона. В кн.: Болезни нервной системы. Под. ред. Яхно НН. Москва: Медицина; 2005; 2. С. 76–96. [Artem'ev DV, Golubev VL, Yakhno NN. Bolezn' Parkinsona. V kn.: Bolezni nervnoy sistemy. Pod. red. Yakhno NN. Moscow: Meditsina; 2005;2. Р. 76–96.]</p><p>Голубев ВЛ. Лечение болезни Паркинсона: решенные и нерешенные вопросы. В кн.: Избранные лекции по неврологии. Под ред. Голубева ВЛ. Mосква: Эйдос Медиа; 2006. С. 395–421. [Golubev VL. Lechenie bolezni Parkinsona: reshennye i nereshennye voprosy. V kn.: Izbrannye lektsii po nevrologii. Pod red. Golubeva VL. Moskva: Eydos Media; 2006. Р. 395–421.]</p><p>Нодель МР. Леводопа: поиски стандартов для «золотого стандарта». Неврологический журнал. 2010;(3):42–7. [Nodel' MR. Levodopa: poiski standartov dlya «zolotogo standarta». Nevrologicheskiy zhurnal. 2010;(3):42–7.]</p><p>Шток ВН, Федорова НВ. Болезнь Паркинсона. В кн.: Экстрапирамидные расстройства. Под ред. Штока ВН и соавт. Москва: MЕДпресс-информ; 2002. С. 94–122. [Shtok VN, Fedorova NV. Bolezn' Parkinsona. V kn.: Ekstrapiramidnye rasstroystva. Pod red. Shtoka VN i soavt. Moscow: MEDpress-inform; 2002. S. 94–122.]</p><p>Ahlskog J, Muenter M. Frequency of lеvodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58. DOI: 10.1002%2Fmds.1090.</p><p>Brotchie J, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson’s disease. J Neural Transm. 2005;112(3):359-91. DOI: 10.1007%2Fs00702-004-0251-7. Epub 2004 Dec 22.</p><p>Olanow CW. The scientific basis for the current treatment of Parkinson’s disease. Ann Rev Med. 2004;55:41–60. DOI: 10.1146%2Fannurev.med.55.091902.104422.</p><p>Stocchi F, Vacca L, Ruggieri S, Olanow SW. Intermittent vs continuous levodopa administration in patient with advanced Parkinson’s disease: a clinical and pharmacokinetic study. Arch. Neurol. 2005;62(6):905–10.</p><p>The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinsons disease: A randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931–8.</p><p>Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson’s disease. Expert Opin Pharmacother. 2009;10(4):677–91. DOI: 10.1517/14656560902746041.</p><p>Rose S, Scheller DKA, Bredenbach A et al. Plasma level of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behav Pharmacol. 2007;18(2):155–60. DOI: 10.1097%2FFBP.0b013e3280ebb400.</p><p>The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinsons disease. Arch Neurol. 2003;60(12):1721–8.</p><p>Watts RL, Jankovic J, Waters C et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinsons disease. Neurology. 2007;68(4):272–6. DOI: 10.1212%2F01.wnl.0000252355.79284. 22 Epub 2007 Jan 3.</p><p>Poewe WH, Rascol O, Giladi N et al. Long-term experience with rotigotine transdermal patch. Eur J Neurol. 2006;13(Suppl 2):322.</p><p>Metman VL, Gillespie M, Farmer C et al. Continuous transdermal dopaminrtgic stimulation in advanced Parkinson’s disease. Clin. Neuropharmacol. 2001;24(3):163–9.</p><p>Lewitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson’s disease treated with rotigotine transdermal system: PREFER study. Neurology. 2007;68(16):1262–7.</p><p>Poewe WH, Rascol O, Quinn N et al. On behalf of the SP515 Investigators. Efficaсy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomized controlled trial. Lancet Neurol. 2007;6(6):513–20.</p><p>Giladi N, Badenhorst F, Boroojerdi B. Effects of rotigotine transdermal patch on early morning and night time motor function in patients with Parkinson’s disease. Eur J Neurol. 2007;14(Suppl 1):67.</p><p>Lewitt PA, Boroojerdi B, Macmahon D et al. Overnight switch from oral dopaminergic agonists to transdermal ritigitine patch in subjects with Parkinson’s disease. Clin Neuropharmacol. 2007;30(5):256–65.</p><p>Perez-Lloret S, Reya MV, Rattia PL, Rascol O. Rotigotine transdermal patch for thetreatment of Parkinson’s Disease. Fundam Clin Pharmacol. 2013;27(1):81–95. DOI: 10.1111/j.1472-8206.2012.01028.x. Epub 2012 Feb 9.</p><p>Giladi N, Boroojerdi B, Korczyn AD et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22(16):2398–404. DOI: 10.1002%2Fmds.21741. 22. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. Mov Disord. 2003;18(6):668–72. DOI: 10.1002%2Fmds.10429.</p><p>Giladi N, Badenhorst F, Boroojerdi B. Patients preference for rotigotine transdermal patch for treatment of Parkinson’s disease. Results of a single-arm, prospective, multinational trial. Eur J Neurol. 2007;14(Suppl 1):67.</p></div><br />

The authors declare that there are no conflicts of interest present.